639 related articles for article (PubMed ID: 12698874)
21. Aggravation of intestinal inflammation by depletion/deficiency of gammadelta T cells in different types of IBD animal models.
Kühl AA; Pawlowski NN; Grollich K; Loddenkemper C; Zeitz M; Hoffmann JC
J Leukoc Biol; 2007 Jan; 81(1):168-75. PubMed ID: 17041003
[TBL] [Abstract][Full Text] [Related]
22. The opioid antagonist naltrexone improves murine inflammatory bowel disease.
Matters GL; Harms JF; McGovern C; Fitzpatrick L; Parikh A; Nilo N; Smith JP
J Immunotoxicol; 2008 Apr; 5(2):179-87. PubMed ID: 18569389
[TBL] [Abstract][Full Text] [Related]
23. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis.
Araki A; Kanai T; Ishikura T; Makita S; Uraushihara K; Iiyama R; Totsuka T; Takeda K; Akira S; Watanabe M
J Gastroenterol; 2005 Jan; 40(1):16-23. PubMed ID: 15692785
[TBL] [Abstract][Full Text] [Related]
24. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.
Bertrand V; Quéré S; Guimbaud R; Sogni P; Chauvelot-Moachon L; Tulliez M; Lamarque D; Charreire J; Giroud JP; Couturier D; Chaussade S; Breban M
Eur Cytokine Netw; 1998 Jun; 9(2):161-70. PubMed ID: 9681392
[TBL] [Abstract][Full Text] [Related]
25. The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation.
Xu Y; Hunt NH; Bao S
Cell Res; 2008 Dec; 18(12):1220-9. PubMed ID: 19030026
[TBL] [Abstract][Full Text] [Related]
26. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM
J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375
[TBL] [Abstract][Full Text] [Related]
27. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
Duchmann R; Schmitt E; Knolle P; Meyer zum Büschenfelde KH; Neurath M
Eur J Immunol; 1996 Apr; 26(4):934-8. PubMed ID: 8625991
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.
Lamprecht A; Ubrich N; Yamamoto H; Schäfer U; Takeuchi H; Maincent P; Kawashima Y; Lehr CM
J Pharmacol Exp Ther; 2001 Nov; 299(2):775-81. PubMed ID: 11602694
[TBL] [Abstract][Full Text] [Related]
29. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
30. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells.
Sasaoka T; Ito M; Yamashita J; Nakajima K; Tanaka I; Narita M; Hara Y; Hada K; Takahashi M; Ohno Y; Matsuo T; Kaneshiro Y; Tanaka H; Kaneko K
Am J Physiol Gastrointest Liver Physiol; 2011 Apr; 300(4):G568-76. PubMed ID: 21193526
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Aharoni R; Kayhan B; Brenner O; Domev H; Labunskay G; Arnon R
J Pharmacol Exp Ther; 2006 Jul; 318(1):68-78. PubMed ID: 16624971
[TBL] [Abstract][Full Text] [Related]
32. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
33. 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.
Narushima S; DiMeo D; Tian J; Zhang J; Liu D; Berg DJ
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G477-88. PubMed ID: 18048478
[TBL] [Abstract][Full Text] [Related]
34. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H
Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179
[TBL] [Abstract][Full Text] [Related]
36. Regulation of gut inflammation and th17 cell response by interleukin-21.
Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G
Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085
[TBL] [Abstract][Full Text] [Related]
37. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease.
Yadav VR; Suresh S; Devi K; Yadav S
J Pharm Pharmacol; 2009 Mar; 61(3):311-21. PubMed ID: 19222903
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
39. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]